Business Context and Reporting Period
Company: Relmada Therapeutics, Inc. (RLMD)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Overview: Relmada is a clinical-stage biotechnology company. Following a strategic review in late 2024 due to the futility of its lead candidate (Esmethadone/REL-1017) for Major Depressive Disorder, the Company pivoted to acquiring new assets. Key pipeline programs include NDV-01 (bladder cancer) and Sepranolone (neurological disorders). The psilocybin program (REL-P11) was terminated in May 2025.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(17,559,465) | $(21,828,126) |
| Loss Per Share (Basic & Diluted) | $(0.58) | $(0.72) |
| Operating Expenses | $18,218,435 | $22,987,860 |
| Operating Cash Flow | $(18,067,033) | $(13,036,748) |
| Cash & Cash Equivalents (End of Period) | $1,149,706 | $1,335,018 |
| Short-term Investments | $25,911,326 | $41,052,356 |
| Total Current Assets | $27,657,442 | $45,795,843 |
| Total Current Liabilities | $5,231,421 | $10,291,390 |
| Stockholders' Equity | $22,440,491 | $35,521,961 |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately $4.77 million (21%) compared to Q1 2024. This was driven by a $3.4 million decrease in General and Administrative (G&A) expenses and a $1.35 million decrease in Research and Development (R&D) expenses.
- R&D Shift: While R&D expenses decreased overall, this masked a $4.79 million increase in clinical study costs related to the new NDV-01 and Sepranolone programs, offset by a $5.27 million decrease in costs associated with winding down the REL-1017 program.
- Liquidity Position: Cash and cash equivalents decreased by $2.71 million during the quarter. Short-term investments decreased by approximately $15.14 million, primarily due to sales of investments to fund operations and new acquisitions.
- Stock Issuance: The Company issued 3,017,420 shares of restricted common stock (valued at ~$905,000) as part of the upfront consideration for the NDV-01 license agreement.
Guidance, Outlook, Risks, and Unusual Items
Strategic Transactions & Outlook
- NDV-01 Acquisition: In March 2025, Relmada licensed NDV-01 (bladder cancer) from Trigone Pharma. Upfront payment included $3.5 million cash and 3 million shares of stock. Potential milestones total up to $200 million plus 3% royalties.
- Sepranolone Acquisition: In February 2025, Relmada acquired Sepranolone (neurosteroid) from Asarina Pharma for approximately $2.76 million cash.
- Program Termination: The psilocybin program (REL-P11) was terminated in May 2025 due to regulatory changes and strategic realignment.
- Milestones: Anticipated data readouts for NDV-01 include 6-month data in mid-2025 and 12-month data by year-end 2025.
Risks and Contingencies
- Going Concern: The filing includes a "substantial doubt" disclosure regarding the Company's ability to continue as a going concern. Management projects insufficient liquidity to sustain operations for one year following the report date without additional financing.
- Nasdaq Compliance: The Company received a deficiency letter from Nasdaq on January 21, 2025, for failing to meet the $1.00 minimum bid price requirement. It has until July 21, 2025, to regain compliance or face potential delisting.
- Financing Needs: The Company expects to incur additional losses and will require significant capital to fund clinical trials and operations. No assurance exists that financing will be available on favorable terms.
Investor Verification Checklist
- Liquidity Runway: Verify the specific timeline for cash depletion and the status of any ongoing financing efforts (equity/debt) to address the "substantial doubt" going concern warning.
- Nasdaq Status: Monitor the stock price to determine if the Company will meet the $1.00 bid price requirement by the July 21, 2025, compliance deadline to avoid delisting.
- NDV-01 Data: Confirm the timing and results of the upcoming 6-month and 12-month Phase 2 data readouts for NDV-01, which are critical for the asset's valuation.
- Stock Dilution: Review the impact of the 3 million shares issued for the NDV-01 deal and potential future equity raises required to fund the new pipeline.
- REL-1017 Decision: Await the outcome of the comprehensive data review for the paused Esmethadone (REL-1017) program to determine if it will be abandoned or re-purposed.